Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 637.6% in July

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 394,600 shares, a growth of 637.6% from the July 15th total of 53,500 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is presently 0.4 days.

Apollomics Price Performance

Apollomics stock traded down $0.01 during midday trading on Wednesday, reaching $0.13. 4,175,582 shares of the stock traded hands, compared to its average volume of 1,629,893. Apollomics has a 12 month low of $0.12 and a 12 month high of $5.28. The stock’s fifty day moving average is $0.20 and its 200-day moving average is $0.43.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Apollomics stock. Powell Investment Advisors LLC acquired a new position in Apollomics, Inc. (NASDAQ:APLM) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned approximately 0.15% of Apollomics as of its most recent SEC filing. 19.13% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright cut their target price on shares of Apollomics from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.